| DIRECT COMPETITOR COMPARISON | |
| EURX | Pvt1 | ELN | KV-A | Industry | | Market Cap: | 553.18M | N/A | 3.22B | N/A | 93.79M | | Employees: | 526 | N/A | 1,687 | N/A | 65 | | Qtrly Rev Growth (yoy): | 24.60% | N/A | 6.30% | N/A | 19.10% | | Revenue (ttm): | N/A | N/A | 1.08B | N/A | 13.84M | | Gross Margin (ttm): | 39.30% | N/A | 50.57% | N/A | 65.67% | | EBITDA (ttm): | N/A | N/A | 26.80M | N/A | -11.86M | | Oper Margins (ttm): | N/A | N/A | -4.49% | N/A | -149.46% | | Net Income (ttm): | N/A | N/A | 51.00M | N/A | N/A | | EPS (ttm): | N/A | N/A | 0.106 | N/A | -0.31 | | P/E (ttm): | N/A | N/A | 61.79 | N/A | 17.25 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.28 | | P/S (ttm): | N/A | N/A | 2.96 | N/A | 9.83 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 55.80 | 2.24% | 56.48B | 12.17 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 50.07 | 1.25% | 14.48B | 16.76 | | Genzyme Corp. | GENZ | 48.78 | 1.20% | 12.95B | 27.81 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 42.83 | -0.86% | 38.54B | 16.56 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 51.28 | 0.81% | 9.15B | 1046.53 | | Teva Pharmaceutical Industries Limited | TEVA | 52.91 | 0.84% | 46.61B | 48.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 38.09 | 0.42% | 4.04B | 19.63 | | King Pharmaceuticals Inc. | KG | 11.89 | 1.80% | 2.95B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.25 | -0.92% | 5.58B | 111.96 | | Pfizer Inc. | PFE | 18.30 | 0.44% | 147.67B | 15.20 | | Johnson & Johnson | JNJ | 64.37 | -0.16% | 177.60B | 14.06 | | GlaxoSmithKline plc | GSK | 41.80 | -0.36% | 105.96B | 13.53 | | Sanofi-Aventis | SNY | 39.11 | 1.90% | 102.12B | N/A | | Novartis AG | NVS | 54.21 | 0.58% | 123.12B | 16.23 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.95 | 0.70% | N/A | N/A | | AstraZeneca plc | AZN | 45.54 | -0.11% | 66.03B | 9.14 | | Abbott Laboratories | ABT | 53.34 | -0.45% | 82.50B | 14.45 | | Bristol-Myers Squibb Co. | BMY | 25.78 | 0.04% | 51.07B | 13.34 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | ELN | | 3 Reasons to Buy Dendreon Today
Fri 2:34pm -
at Motley Fool | | • | ELN | | Another Acquisition for J&J
Thu, Dec 17 -
Zacks.com | | • | ELN | | Report from Europe: Stocks Recovering After Data Points to Dovish Fed
Wed, Dec 16 -
at Seeking Alpha | | • | ELN | | Five Biotech Events to Watch in 2010
Wed, Dec 16 -
at TheStreet.com | | • | KV-A | | KV PHARMACEUTICAL CO /DE/ Files SEC form 8-K, Other Events
Tue, Dec 15 -
EDGAR Online | | • | KV-A | | KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent
Tue, Dec 15 -
PR Newswire | | • | ELN | | Biotech Stocks: Elan, Gilead Sciences lead drug stocks lower
Tue, Dec 15 -
at MarketWatch | | • | ELN | | Forget the Higher Doses
Tue, Dec 15 -
at Motley Fool | | • | ELN | | Is This Company Really Earning Money?
Tue, Dec 15 -
at Motley Fool | | • | KV-A | | 5 Stocks Bouncing Back
Fri, Dec 11 -
at Motley Fool | | • | KV-A | | 10 Peter Lynch Stocks
Thu, Dec 10 -
at Motley Fool | | • | KV-A | | KV make Van Vliet permanent president and CEO
Wed, Dec 2 -
AP | | | All Headlines for these symbols... |
|
|
|
0.20% Nasdaq 
0.62 (4.88%) 
Competitors
